Central I1-imidazoline receptors as targets of centrally acting antihypertensive drugs. Clinical pharmacology of moxonidine and rilmenidine

Annals of the New York Academy of Sciences

Volumn 881, Issue , 1999, Pages 420-429

  Van Zwieten, P A ^a   Peters, S L M ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; IMIDAZOLINE I1 RECEPTOR; MOXONIDINE; RILMENIDINE; CLONIDINE; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS; OXAZOLE DERIVATIVE;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; DRUG TARGETING; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HEART RATE; HEART STROKE VOLUME; HEMODYNAMICS; HYPERTENSION; LUNG ARTERY PRESSURE; PATHOPHYSIOLOGY; VASCULAR RESISTANCE; VASODILATATION; ANIMAL; BRAIN; CLINICAL TRIAL; DRUG EFFECT; DRUG POTENTIATION; HUMAN; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN; CLINICAL TRIALS; CLONIDINE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION; IMIDAZOLES; OXAZOLES; RECEPTORS, DRUG;

EID: 0032588760     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09390.x     Document Type: Conference Paper

References (33)

1. Chalmers, J. P. & P. M. Pilowski. 1991. Brain stem and bulbospinal neurotransmitter systems in the control of blood pressure. J. Hypertens. 9: 675-694.
2. Van Zwieten, P. A. & J. P. Chalmers. 1994. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc. Drugs Ther. 8: 787-799.
3. Van Zwieten, P. A., M. J. M. C. Thoolen & P. B. M. W. M. Timmermans. 1984. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 6: 28-33.
4. Van Zwieten, P. A., M. J. M. C. Thoolen & P. B. M. W. M. Timmermans. 1984. The pharmacological base of the hypotensive activity and side-effects of α-methyl-DOPA, clonidine and guanfacine. Hypertension 6: 11-28.
5. Prichard, B. N. C., B. Tomlinson & J. C. Renondin. 1989. Urapidil, a multiple action α-blocking drug. Am. J. Cardiol. 64: 11D-15D.
6. Van Zwieten, P. A., G. J. Blauw & P. Van Brummelen. 1992. Serotonergic receptors and drugs in hypertension. Pharmacol. Toxicol. 70: S17-S22.
7. Feldman, J., E. Tibiriça, G. Bricca, M. Dontenwill, A. Belcourt & P. Bousquet. 1990. Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit. Br. J. Pharmacol. 100: 600-604.
8. Michel, M. C. & P. Ernsberger. 1992. Keeping an eye on the I site: Imidazoline- preferring receptors. Trends Pharmacol. Sci. 13: 369-370.
9. 1-imidazoline receptor: From binding site to therapeutic target in cardiovascular disease. J. Hypertens. 15: S9-S23.
10. 1)-receptors as targets of centrally acting antihypertensives: Moxonidine and rilmenidine. J. Hypertens. 15: 117-125.
11. Crisp, P. & A. Faulds. 1992. Moxonidine. Drugs 44: 993-1012.
12. Prichard, B. N. C. & B. R. Graham. 1996. Effective antihypertensive therapy: Blood pressure control with moxonidine. J. Cardiovasc. Pharmacol. 27: S38-S48.
13. Mitrovic, V., W. Patyna J., Hüting & W. Schlepper. 1991. Haemodynamic and neurohormonal effects of moxonidine in patients with essential hypertension. Cardiovasc. Drugs Ther. 5: 967-972.
14. 1-Imidazoline Receptor Agonist Moxonidine: A New Antihypertensive, 2nd Ed. P.A. van Zwieten, C.A. Hamilton, S. Julius & B.N.C. Prichard, Eds.: 49-77. Royal Society of Medicine Press Ltd. London.
15. Eichstädt, H., W. Richter & M. Bäder. 1989. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc. Drugs Ther. 3: 583-587.
16. N'Guyen Van Cao, S., B. Levy & R. Slama. 1988. Non-invasive study of cardiac structure and function after rilmenidine for essential hypertension. Am. J. Cardiol. 61: 72D-75D.
17. Weimann, H. J. & M. Rudolph. 1992. Clinical pharmacokinetics of moxonidine. J. Cardiovasc. Pharmacol. 20: S37-S41.
18. Kirch, W., H. J. Hutt & V. Plänitz. 1988. The influence of renal function on clinical pharmacokinetics of moxonidine. Clin. Pharmacokin. 15: 245-253.
19. Aparicio, M., M. Dratwa & N. El Esper. 1994. Pharmacokinetics of rilmenidine in patients with chronic renal insufficiency and in hemodialysis patients. Am. J. Cardiol. 74: 43A-50A.
20. 1-Imidazoline Receptor Agonist Moxonidine: A New Antihypertensive. 2nd Ed. P. A. van Zwieten, C. A. Hamilton, S. Julius, B. N. C. Prichard Eds.: 31-47. Royal Society of Medicine Press. London.
21. United Kingdom Working Party On Rilmenidine. 1990. Rilmenidine in mild-to-moderate essental hypertension. Curr. Ther. Res. 1: 194-211.
22. Filastre, J. P., B. Letac, F. Galinier, G. Le Bihan & J. Schwartz. 1988. A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patient. Am. J. Cardiol. 61: 81D-85D.
23. Frei, M., L. Küster & P. P. Gardosch Von Krosigk. 1994. Moxonidine and hydrochlorothiazide in combination: A synergistic antihypertensive effect. J. Cardiovasc. Pharmacol. 24: S25-S28.
24. Fiorentini, C., C. Guillet & M. Guazzi. 1989. A multicentre double-blind trial comparing rilmenidine 1 mg and hydrochlorothiazide in 244 patients. Arch. Mal. Coeur Vaiss. 82: 39-46.
25. Rupp, H., B. Maisch & C. Brilla. 1996. Drug withdrawal and rebound hypertension. Differential action of the central antihypertensive drugs moxonidine and clonidine. Cardiovasc. Drugs Ther. 10: 251-262.
26. Tamm, M., C. Sieber, F. Schnyder & W. Haefeli. 1997. Moxonidine-induced cholestatic hepatitis. Lancet 350: 1822.
27. Morrison, P. J., C. Corcoran & P. Vivet. 1990. Effect of rilmenidine on alertness. JAMA (French ed.) July: 27-28.
28. Krentz, A. J. & A. J. Evans. 1998. Selective imidazoline receptor agonists for metabolic syndrome. Lancet 351: 152-154.
29. Ernsberger, P., R. J. Koletsky, L. A. Collins & B. Bedol. 1996. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc. Drugs Ther. 10: 275-282.
30. Rosen P., P. Ohly & H. Gleichman. 1997. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J. Hypertens. 15: S31-S38.
31. Kaan, E. C., R. Bruckner, P. Frohly, M. Tulp, S. G. Scharer & D. Ziegler. 1995. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc. Risk Fact. 5: 19-27.
32. Swedberg, K. 1997. Results of a phase II dose response trial of moxonidine in CHF. In Sympathetic Neurohumoral Modulation in Cardiovascular Disease. M. Esler, Ed. Symposium, Cologne.
33. Julius, S. 1995. Sympathetic overactivity and the pathophysiology of coronary risk in hypertension. Cardiovasc. Risk Fact. 5: 2-10.